

Global Oral Proteins & Peptides Market Size study, by Molecule (Semaglutide, Linaclotide, Calcitonin), by Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), by Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), by Formulation (Tablet, Capsule), and Regional Forecasts 2022-2032

https://marketpublishers.com/r/G1C6F51DBB56EN.html

Date: January 2025 Pages: 285 Price: US\$ 3,218.00 (Single User License) ID: G1C6F51DBB56EN

## **Abstracts**

The Global Oral Proteins & Peptides Market is valued at approximately USD 6.03 billion in 2023 and is anticipated to grow at an impressive CAGR of 22.5% over the forecast period 2024-2032, reaching USD 20.37 billion by 2032. This market encompasses a wide array of proteins and peptides administered orally, offering innovative therapeutic approaches for chronic conditions such as diabetes, gastroenterology disorders, and genetic diseases.

Several factors are driving this market growth, including the rising prevalence of chronic diseases, the enhanced patient compliance associated with oral drug formulations, and increasing collaborations between pharmaceutical giants for R&D. The oral route of administration ensures better patient adherence, significantly improving therapeutic outcomes. Despite these advantages, the market faces challenges related to the stability and formulation of oral proteins and peptides, alongside the stringent regulatory hurdles that new formulations must overcome.

The semaglutide molecule segment holds the largest share in the market. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide plays a pivotal role in managing type-2 diabetes. Its growing adoption is fueled by its ability to regulate blood sugar levels and appetite, addressing the needs of a significant diabetic population. Additionally, the tablet formulation segment is poised for the highest growth during the



forecast period due to its cost-effectiveness, longer shelf life, and stability, which ensure greater scalability and accessibility for commercial production.

Geographically, Europe stands out as the second-largest market for oral proteins and peptides, owing to its favorable regulatory environment, reimbursement policies, and the presence of key players. North America, however, continues to lead due to its robust healthcare infrastructure and ongoing advancements in pharmaceutical research.

The competitive landscape is marked by prominent players such as Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), and AstraZeneca (UK), among others. These companies are actively driving innovation and expanding the availability of oral protein and peptide therapies globally.

The detailed segmentation of the market is as follows:

By Molecule

Semaglutide

Linaclotide

Calcitonin

Trofinetide

Voclosporin

Plecanatide

#### By Drug Class

**GLP-1** Receptor Agonist

GEP

CGRP



By Therapeutic Area

Diabetes

Gastroenterology

Genetic Disorder

#### By Formulation

Tablet

Capsule

**Oral Solution** 

By Region:

North America

U.S.

Canada

### Europe

UK

Germany

France

Spain

Italy



### Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

**Rest of Asia Pacific** 

Latin America

Brazil

Mexico

**Rest of Latin America** 

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years Considered for the Study

Historical Year: 2022

Global Oral Proteins & Peptides Market Size study, by Molecule (Semaglutide, Linaclotide, Calcitonin), by Drug...



Base Year: 2023

Forecast Period: 2024–2032

Key Takeaways:

Market Estimates & Forecasts for 10 years (2022–2032).

Annualized revenue analysis and regional breakdown for each market segment.

Detailed analysis of geographical landscape with country-level trends.

Insights into competitive strategies and market innovations.

Analysis of market drivers, challenges, and opportunities.



# Contents

### CHAPTER 1. GLOBAL ORAL PROTEINS & PEPTIDES MARKET EXECUTIVE SUMMARY

- 1.1. Global Oral Proteins & Peptides Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Molecule
- 1.3.2. By Drug Class
- 1.3.3. By Therapeutic Area
- 1.3.4. By Formulation
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendations & Conclusion

# CHAPTER 2. GLOBAL ORAL PROTEINS & PEPTIDES MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objectives
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply-Side Analysis
  - 2.3.4. Demand-Side Analysis
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

### CHAPTER 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET DYNAMICS

- 3.1. Market Drivers
  - 3.1.1. Rising Prevalence of Chronic Diseases
  - 3.1.2. Patient Compliance for Oral Administration
  - 3.1.3. Increased Collaborations for R&D
- 3.2. Market Challenges
  - 3.2.1. Formulation and Stability Issues
  - 3.2.2. Stringent Regulatory Approvals



- 3.3. Market Opportunities
  - 3.3.1. Innovations in Drug Delivery Systems
- 3.3.2. Expansion into Emerging Markets

## CHAPTER 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET INDUSTRY ANALYSIS

- 4.1. Porter's Five Forces Analysis
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. PESTEL Analysis
- 4.3. Investment Opportunities
- 4.4. Winning Strategies
- 4.5. Disruptive Trends

# CHAPTER 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE & FORECASTS BY MOLECULE (2022–2032)

- 5.1. Segment Dashboard
- 5.2. Semaglutide
- 5.3. Linaclotide
- 5.4. Calcitonin
- 5.5. Trofinetide
- 5.6. Voclosporin
- 5.7. Plecanatide

# CHAPTER 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE & FORECASTS BY DRUG CLASS (2022–2032)

- 6.1. Segment Dashboard
- 6.2. GLP-1 Receptor Agonist
- 6.3. GEP (Gastrointestinal Endocrine Peptides)
- 6.4. CGRP (Calcitonin Gene-Related Peptide)

# CHAPTER 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE & FORECASTS BY THERAPEUTIC AREA (2022–2032)

Global Oral Proteins & Peptides Market Size study, by Molecule (Semaglutide, Linaclotide, Calcitonin), by Drug...



- 7.1. Segment Dashboard
- 7.2. Diabetes
- 7.3. Gastroenterology
- 7.4. Genetic Disorders

# CHAPTER 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE & FORECASTS BY FORMULATION (2022–2032)

- 8.1. Segment Dashboard
- 8.2. Tablet
- 8.2.1. Immediate-Release Tablets
- 8.2.2. Controlled-Release Tablets
- 8.2.3. Orally Disintegrating Tablets
- 8.3. Capsule
  - 8.3.1. Gelatin-Based Capsules
- 8.3.2. Non-Gelatin Capsules
- 8.3.3. Liquid-Filled Capsules
- 8.4. Oral Solution
  - 8.4.1. Ready-to-Drink Solutions
  - 8.4.2. Powder-Based Oral Reconstitution

# CHAPTER 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE & FORECASTS BY REGION (2022–2032)

- 9.1. North America
- 9.2. Europe
- 9.3. Asia Pacific
- 9.4. Latin America
- 9.5. Middle East & Africa

### CHAPTER 10. COMPETITIVE INTELLIGENCE

- 10.1. Key Company SWOT Analysis
  - 10.1.1. Novo Nordisk A/S
  - 10.1.2. AbbVie Inc.
- 10.1.3. Pfizer Inc.
- 10.2. Top Market Strategies
- 10.3. Emerging Players Analysis



### CHAPTER 11. RESEARCH PROCESS

- 11.1. Research Attributes
- 11.2. Data Collection and Analysis

#### 12. LIST OF TABLES

### 1. GLOBAL ORAL PROTEINS & PEPTIDES MARKET BY MOLECULE, 2022–2032

- 2. GLOBAL MARKET BY DRUG CLASS, 2022–2032
- 3. REVENUE CONTRIBUTION BY THERAPEUTIC AREA, 2022–2032
- 4. FORMULATION SEGMENTATION ANALYSIS, 2022–2032

#### 5. REGIONAL BREAKDOWN BY REVENUE, 2022–2032

'This list is not complete; the final report includes over 100 tables. The list may be updated.'

#### **12. LIST OF FIGURES**

### 1. MARKET SIZE TRENDS AND FORECASTS, 2022–2032

- 2. KEY MOLECULE REVENUE ANALYSIS, 2023
- 3. REGIONAL MARKET SHARE ANALYSIS, 2023
- 4. SWOT ANALYSIS FOR TOP COMPANIES

#### 5. GROWTH DRIVERS AND CHALLENGES OVERVIEW

'This list is not complete; the final report includes over 50 figures. The list may be updated.'



### I would like to order

- Product name: Global Oral Proteins & Peptides Market Size study, by Molecule (Semaglutide, Linaclotide, Calcitonin), by Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), by Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), by Formulation (Tablet, Capsule), and Regional Forecasts 2022-2032
  - Product link: https://marketpublishers.com/r/G1C6F51DBB56EN.html
    - Price: US\$ 3,218.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/G1C6F51DBB56EN.html</u>